Maria L Padilla, MD
- PROFESSOR | Medicine, Pulmonary, Critical Care and Sleep Medicine
After completing her pulmonary fellowship at Mount Sinai School of Medicine and The Mount Sinai Medical Center, Dr. Padilla pursued her studies in lung transplantation by attending the programs at Toronto General Hospital and Stanford University. She was the co-founder of the program at The Mount Sinai Hospital in New York City. During her fellowship training, Dr. Padilla conducted research in pathology, developing models of pulmonary diseases under the mentorship of Dr. Jerome Kleinerman. She also participated in clinical research in Sarcoidosis and Interstitial Lung Diseases. She is a United Network for Organ Sharing (UNOS) certified transplant pulmonologist and a member of the International Society of Heart and Lung Transplantation (ISHLT). She served on the editorial and scientific advisory boards of the World Association of Sarcoidsosis and Other Granulomatous Diseases (WASOG). Dr. Padilla is a committee member of the Interstitial Lung Disease Network of the American College of Chest Physicians, and is also a steering committee member of the Pulmonary Fibrosis Indentification: Lessons for Optimizing Treatment (PILOT). She serves on the medical advisory boards of the Coalition for Pulmonary Fibrosis, the Sarcoidosis Research Foundation, the Hermansky Pudlak Syndrome Network, and the Scleroderma Foundation, Tri-State Chapter. She is a graduate of the Executive Leadership of American Medicine (ELAM) program.
Dr. Padilla is board certified in Internal Medicine, Pulmonary Medicine and Critical Care Medicine. She is the Director of the Advanced Lung /Interstitial Lung Disease Program and the Medical Director of the Lung Transplantation Program at The Mount Sinai Medical Center. She is also involved in the Sarcoidosis Service and the adult Cystic Fibrosis program. She is a consultant to other transplant programs at our institution, and is also the principal investigator of clinical research projects. Dr. Padilla specializes in the treatment of diffuse interstitial lung diseases, including idiopathic interstital pneumonia, acute interstital pneumonia, lymphocytic interstital pneumonia, non-specific interstital pneumonia, organizing pneumonia, bronchiollitis obliterans, and hypersensitivity pneumonia. She also specializes in lung diseases associated with rheumatologic disorders, such as rheumatoid arthritis, dermatomyositis, mixed connective tissue disease, and systemic lupus erythematosus. In addition, she also treats drug-induced lung disease, mycobacterial lung disease, Langerhans cell hystiocytosis, lymphangioleimyomatosis, pulmonary vasculitis, alveolar hemorrhage, and pulmonary alveolar proteinosis.
American Board of Internal Medicine
- Allergic Bronchopulmonary Aspergillosis (ABPA)
- Arterial Blood Gases
- Heart-Lung Transplant
- Idiopathic Pulmonary Fibrosis
- Lung Transplant
- Oxygen Therapy
- Pneumococcal Vaccine
- Pulmonary Embolism
- Pulmonary Function Tests
- Pulmonary Hypertension
MD, Mount Sinai School of Medicine
Residency, Internal Medicine, Mount Sinai Hospital
Fellowship, Pulmonary, Mount Sinai Hospital
The Dr Sidney Grossman Distinguished Humanitarian Award
Healthcare Foundation of New Jersey Humanism in Medicine Faculty Award\t
2000 Physician of the Year Award
Saul Horowitz Jr. Memorial Award
Distinguished Service Award
Distinguished Teacher Award
Henry and Catherine Gaisman Fellowship
Pulmonary Academic Award (NIH)\t
American Lung Association Fellowship
Dr. Alan Guttmacher Award
Alpha Omega Alpha
Max Som Scholarship
Dr. Padilla's research interests include investigation of fibrogenesis and the various manifestations of this process in different diseases (Idiopathic Pulmonary Fibrosis, Sarcoidosis, Collagen Vascular associated pulmonary fibrosis, genetic associated pulmonary fibrosis, Hermansky Pudlak Syndrome, bronchiolitis obliterans among others). She conducts clinical investigations in the treatment and course of these diseases and participates in collaborative multicenter studies to advance the understanding and knowledge of these illnesses. She is the principal investigator of the INSPIRE trial investigating the safety and efficacy of Interferon gamma on the survival of patients with Idiopathic Pulmonary Fibrosis. Additional studies investigating early markers of interstitial lung disease, therapies for secondary pulmonary hypertension and the efficacy of certain agents on the pulmonary fibrosis associated with Hermansky Pudlak Syndrome, are in development.
- A Phase II Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis
The purpose of this study is to find out what effects good or bad lebrikizumab or placebo treatment has on subjects and their Idiopathic Pulmonary Fibrosis (IPF). Lebrikizumab is considered “investigational” because it has not been approved by the U.S. Food and Drug Administra...
- A Phase 2 Open-label Dose-Escalation Study to Evaluate the Safety Tolerability and Efficacy of FG-3019 in Subjects with Idiopathic Pulmonary Fibrosis [Protocol Number FGCL-3019-049]
This Phase 2a open-label, single-arm, multicenter trial study will evaluate the safety, tolerability, and efficacy of FG-3019 at a dose of 15 mg/kg in subjects 35 to 80 years of age who have IPF with evidence of disease progression.
The total duration of a subject’s ...
- A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD)
The purpose of this study is to investigate how well the treatment with the study drug called nintedanib can demonstrate a slowing the rate of lung scarring (or fibrosis) and how well the study treatment has an effect on the skin thickening. In addition, this study will ...